Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(07): 723-730
DOI: 10.1055/a-0871-6831
GebFra Science
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Is There a Relationship Between Vitamin D Deficiency Status and PCOS in Infertile Women?

Gibt es eine Beziehung zwischen Vitamin-D-Mangel und PCOS bei unfruchtbaren Frauen?
Emine Arslan
Hitit University Faculty of Medicine, Department of Obstetrics and Gynecology, Corum, Turkey
,
Umit Gorkem
Hitit University Faculty of Medicine, Department of Obstetrics and Gynecology, Corum, Turkey
,
Cihan Togrul
Hitit University Faculty of Medicine, Department of Obstetrics and Gynecology, Corum, Turkey
› Author Affiliations
Further Information

Publication History

received 13 October 2018
revised 06 February 2019

accepted 07 March 2019

Publication Date:
10 July 2019 (online)

Also available at
   Permissions and Reprints

Abstract

Introduction It is still unclear in the literature whether low vitamin D levels play a role in the pathogenesis of polycystic ovary syndrome (PCOS), especially with respect to the regulation of anti-Müllerian hormone (AMH). Therefore, we aimed to investigate whether there could be a relationship between vitamin D deficiency status and PCOS.

Materials and Methods A total of 146 infertile women were divided into two groups according to their ovarian reserve patterns: (i) normal (NOR), and (ii) high (PCOS). The participants were also categorized into two groups according to vitamin D concentrations: (i) Group A < 10 ng/mL, and (ii) Group B 10 – 20 ng/mL. Samples were obtained and analyzed for estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone (TT), 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate (DHEA-S) and AMH.

Results In the NOR group, there were significant differences between Group A and Group B in terms of anthropometric characteristics (p < 0.05, for all). The women in both Group A and Group B had similar AMH concentrations (p > 0.005). Only the NOR group showed a significant though moderate negative correlation between 25(OH)D levels and anthropometric parameters. AMH levels were not correlated with 25(OH)D levels in the NOR or the PCOS group (r = − 0.112, p = 0.008; r = 0.027, p = 0.836). Multivariate regression analysis showed no impact of 25(OH)D on other study parameters. Only AMH measurements were significant enough (p < 0.001) to differentiate between PCOS and NOR patterns.

Conclusion We found no difference in serum 25(OH)D and AMH levels between women with and women without PCOS. No correlation could be demonstrated between 25(OH)D and AMH in the PCOS group or controls.

Zusammenfassung

Einleitung In der Literatur ist immer noch unklar, ob ein niedriger Vitamin-D-Spiegel eine Rolle bei der Pathogenese von polyzystischem Ovarialsyndrom (PCOS) spielt, besonders in Bezug auf die Regulierung des Anti-Müller-Hormons (AMH). Ziel dieser Studie war es daher zu untersuchen, ob es eine Beziehung zwischen Vitamin-D-Mangel und PCOS gibt.

Material und Methoden Es wurden insgesamt 146 unfruchtbare Frauen in die Studie aufgenommen und entsprechend ihrer ovariellen Reserve in 2 Gruppen eingeteilt: (i) normale ovarielle Reserve (NOR), und (ii) hohe ovarielle Reserve (PCOS). Die Teilnehmerinnen wurden zusätzlich je nach Vitamin-D-Spiegel in 1 von 2 Gruppen unterteilt: (i) Gruppe A < 10 ng/mL, und (ii) Gruppe B 10 – 20 ng/mL. Den Teilnehmerinnen wurden Blutproben zur Bestimmung von Östradiol (E2), follikelstimulierendem Hormon (FSH), luteinisierendem Hormon (LH), Gesamttestosteron (TT), 17-Hydroxyprogesteron (17-OHP), Dehydroepiandrosteron-Sulfat (DHEA-S) und AMH entnommen.

Ergebnisse In der NOR-Gruppe gab es signifikante Unterschiede zwischen Gruppe A und Gruppe B hinsichtlich der anthropometrischen Daten (p < 0,05, für alle Gruppen). Die AMH-Konzentrationen waren ähnlich für Frauen aus Gruppe A und Frauen aus Gruppe B (p > 0,005). Nur bei der NOR-Gruppe fand sich eine signifikante moderate negative Korrelation zwischen 25(OH)D-Spiegel und anthropometrischen Parametern. AMH-Werte korrelierten weder in the NOR-Gruppe noch in der PCOS-Gruppe mit 25(OH)D-Werten (r = − 0,112, p = 0,008; r = 0,027, p = 0,836). Bei der multivariaten Regressionsanalyse zeigten sich keine Auswirkungen von 25(OH)D-Werten auf andere Studienparameter. Nur die AMH-Werte waren signifikant genug (p < 0,001), um zwischen PCOS und NOR zu unterscheiden.

Schlussfolgerung Wir fanden keinen Unterschied in den 25(OH)D-Werten und den AMH-Werten zwischen Frauen mit und Frauen ohne PCOS. Es gab keine Hinweise auf eine Korrelation zwischen 25(OH)D-Werten und AMH-Werten in der PCOS-Gruppe und der Kontrollgruppe.

Key words

vitamin D - polycystic ovary syndrome - PCOS - anti-Müllerian hormone - AMH

Schlüsselwörter

Vitamin D - polyzystisches Ovarialsyndrom - PCOS - Anti-Müller-Hormon - AMH
 

  • References

  • 1 Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236
    CrossrefPubMedGoogle Scholar
  • 2 Üstüner I, Sönmezer M, Atabekoğlu C. et al. Chronic Inflammation in Women with Polycystic Ovarian Syndrome. Gynecol Obstet Reprod Med 2006; 12: 180-185
    PubMedGoogle Scholar
  • 3 Qi X, Pang Y, Qiao J. The role of anti-Müllerian hormone in the pathogenesis and pathophysiological characteristics of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2016; 199: 82-87
    CrossrefPubMedGoogle Scholar
  • 4 Parahuleva N, Pehlivanov B, Orbecova M. et al. Serum levels of anti-mullerian hormone in women with polycystic ovary syndrome and healthy women of reproductive age. Akush Ginekol (Sofiia) 2013; 52 (Suppl. 01) 16-23
    PubMedGoogle Scholar
  • 5 Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-856
    CrossrefPubMedGoogle Scholar
  • 6 Parikh G, Varadinova M, Suwandhi P. et al. Vitamin D regulates steroidogenesis and insulin-like growth factor binding protein-1 (IGFBP-1) production in human ovarian cells. Horm Metab Res 2010; 42: 754-757
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Muscogiuri G, Mitri J, Mathieu C. et al. Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease. Eur J Endocrinol 2014; 17: R101-R110
    PubMedGoogle Scholar
  • 8 Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 77: 343-350
    CrossrefPubMedGoogle Scholar
  • 9 Tsakova AD, Gateva AT, Kamenov ZA. 25(OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int J Vitam Nutr Res 2012; 82: 399-404
    CrossrefPubMedGoogle Scholar
  • 10 Yildizhan R, Kurdoglu M, Adali E. et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet 2009; 280: 559-563
    CrossrefPubMedGoogle Scholar
  • 11 Solak I, Cihan FG, Mercan S. et al. Evaluation of 25-Hydroxyvitamin D Levels in Central Anatolia, Turkey. Biomed Res Int 2018; 2018: 4076548
    PubMedGoogle Scholar
  • 12 Wehr E, Trummer O, Giuliani A. et al. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol 2011; 164: 741-749
    CrossrefPubMedGoogle Scholar
  • 13 Li HW, Brereton RE, Anderson RA. et al. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011; 60: 1475-1481
    CrossrefPubMedGoogle Scholar
  • 14 Wehr E, Pilz S, Schweighofer N. et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 575-582
    CrossrefPubMedGoogle Scholar
  • 15 Rashidi B, Haghollahi F, Shariat M. et al. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol 2009; 48: 142-147
    CrossrefPubMedGoogle Scholar
  • 16 Firouzabadi Rd, Aflatoonian A, Modarresi S. et al. Therapeutic effects of calcium and vitamin D supplementation in women with PCOS. Complement Ther Clin Pract 2012; 18: 85-88
    CrossrefPubMedGoogle Scholar
  • 17 Gallea M, Granzotto M, Azzolini S. et al. Insulin and body weight but not hyperandrogenism seem involved in seasonal serum 25-OH-vitamin D3 levels in subjects affected by PCOS. Gynecol Endocrinol 2014; 30: 739-745
    CrossrefPubMedGoogle Scholar
  • 18 Mahmoudi T. Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. Fertil Steril 2009; 92: 1381-1383
    CrossrefPubMedGoogle Scholar
  • 19 Görkem Ü, Küçükler F, Toğrul C. et al. Vitamin D Does not Have Any Impact on Ovarian Reserve Markers in Infertile Women. Gynecol Obstet Reprod Med 2017; 23: 79-83
    CrossrefPubMedGoogle Scholar
  • 20 Shapiro AJ, Darmon SK, Barad DH. et al. Vitamin D levels are not associated with ovarian reserve in a group of infertile women with a high prevalance of diminished ovarian reserve. Fertil Steril 2018; 110: 761-766.e1
    CrossrefPubMedGoogle Scholar
  • 21 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
    PubMedGoogle Scholar
  • 22 Kim JJ, Choi YM, Chae SJ. et al. Vitamin D deficiency in women with polycystic ovary syndrome. Clin Exp Reprod Med 2014; 41: 80-85
    CrossrefPubMedGoogle Scholar
  • 23 Mahmoudi T, Gourabi H, Ashrafi M. et al. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril 2010; 93: 1208-1214
    CrossrefPubMedGoogle Scholar
  • 24 Ngo DT, Chan WP, Rajendran S. et al. Determinants of insulin responsiveness in young women: impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide 2011; 25: 326-330
    CrossrefPubMedGoogle Scholar
  • 25 Panidis D, Balaris C, Farmakiotis D. et al. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem 2005; 51: 1691-1697
    CrossrefPubMedGoogle Scholar
  • 26 Wehr E, Trummer O, Giuliani A. et al. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol 2011; 164: 741-749
    CrossrefPubMedGoogle Scholar
  • 27 Mazloomi S, Sharifi F, Hajihosseini R. et al. Association between hypoadiponectinemia and low serum concentrations of calcium and vitamin D in women with polycystic ovary syndrome. ISRN Endocrinol 2012; 2012: 949427
    PubMedGoogle Scholar
  • 28 He C, Lin Z, Robb SW. et al. Serum vitamin D levels and polycystic ovary syndrome: a systematic review and meta-analysis. Nutrients 2015; 7: 4555-4577
    CrossrefPubMedGoogle Scholar
  • 29 Pearce K, Gleeson K, Tremellen K. Serum anti-Mullerian hormone production is not correlated with seasonal fluctuations of vitamin D status in ovulatory or PCOS women. Hum Reprod 2015; 30: 2171-2177
    CrossrefPubMedGoogle Scholar
  • 30 He C, Lin Z, Robb SW. et al. Serum vitamin D levels and polycystic ovary syndrome: a systematic review and meta-analysis. Nutrients 2015; 7: 4555-4577
    CrossrefPubMedGoogle Scholar
  • 31 Merhi ZO, Seifer DB, Weedon J. et al. Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Womenʼs Interagency HIV Study. Fertil Steril 2012; 98: 228-234
    CrossrefPubMedGoogle Scholar
  • 32 Dennis NA, Houghton LA, Jones GT. et al. The level of serum anti-Müllerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab 2012; 97: 2450-2455
    CrossrefPubMedGoogle Scholar
  • 33 Tehrani FR, Simbar M, Tohidi M. et al. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011; 9: 39
    CrossrefPubMedGoogle Scholar
  • 34 Skałba P, Cygal A, Madej P. et al. Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?. Eur J Obstet Gynecol Reprod Biol 2011; 158: 254-259
    CrossrefPubMedGoogle Scholar
  • 35 Bakeer E, Radwan R, El Mandoury A. et al. Anti-Müllerian Hormone as a Diagnostic Marker in Egyptian Infertile Polycystic Ovary Syndrome Females: Correlations with Vitamin D, Total Testosterone, Dyslipidemia and Anthropometric Parameters. J Med Biochem 2018; 37: 448-455
    CrossrefPubMedGoogle Scholar
  • 36 Wood JR, Ho CK, Nelson-Degrave VL. et al. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J Reprod Immunol 2004; 63: 51-60
    CrossrefPubMedGoogle Scholar
  • 37 Dewailly D, Andersen CY, Balen A. et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014; 20: 370-385
    CrossrefPubMedGoogle Scholar
  • 38 Kozakowski J, Kapuścińska R, Zgliczyński W. Associations of vitamin D concentration with metabolic and hormonal indices in women with polycystic ovary syndrome presenting abdominal and gynoidal type of obesity. Ginekol Pol 2014; 85: 765-770
    PubMedGoogle Scholar
  • 39 Muscogiuri G, Policola C, Prioletta A. et al. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?. Clin Nutr 2012; 31: 476-480
    CrossrefPubMedGoogle Scholar
  • 40 Savastano S, Valentino R, Di Somma C. et al. Serum 25-hydroxyvitamin D Levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS. Nutr Metab (Lond) 2011; 8: 84
    CrossrefPubMedGoogle Scholar
  • 41 Vimaleswaran KS, Berry DJ, Lu C. et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med 2013; 10: e1001383
    CrossrefPubMedGoogle Scholar
  • 42 Legro RS. Obesity and PCOS: Implications for diagnosis and treatment. Semin Reprod Med 2012; 30: 496-506
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Legro RS, Arslanian SA, Ehrmann DA. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-4592
    CrossrefPubMedGoogle Scholar
  • 44 Lie F, Schipper I, de Jong FH. et al. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril 2011; 96: 459-463
    CrossrefPubMedGoogle Scholar
  • 45 Laven JS, Mulders AG, Visser JA. et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: 318-323
    CrossrefPubMedGoogle Scholar
  • 46 Maciel GA, Baracat EC, Benda JA. Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5321-5327
    CrossrefPubMedGoogle Scholar
  • 47 Pigny P, Merlen E, Robert Y. et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003; 88: 5957-5962
    CrossrefPubMedGoogle Scholar
  • 48 Piouka A, Farmakiotis D, Katsikis I. et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009; 296: E238-E243
    CrossrefPubMedGoogle Scholar
  • 49 Tal R, Seifer DB, Khanimov M. et al. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol 2014; 211: 59.e1-59.e8
    CrossrefPubMedGoogle Scholar
  • 50 Sova H, Unkila-Kallio L, Tiitinen A. et al. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes. Gynecol Endocrinol 2019; DOI: 10.1080/09513590.2018.1559807.
    CrossrefPubMedGoogle Scholar
  • 51 Yue CY, Lu LK, Li M. et al. Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS One 2018; 13: e0203129
    CrossrefPubMedGoogle Scholar
  • 52 Wongwananuruk T, Panichyawat N, Indhavivadhana S. et al. Accuracy of anti-Müllerian hormone and total follicles count to diagnose polycystic ovary syndrome in reproductive women. Taiwan J Obstet Gynecol 2018; 57: 499-506
    CrossrefPubMedGoogle Scholar
  • 53 Arslan S, Akdevelioğlu Y. The Relationship Between Female Reproductive Functions and Vitamin D. J Am Coll Nutr 2018; 37: 546-551
    CrossrefPubMedGoogle Scholar
  • 54 Nachtigal MW, Ingraham HA. Bioactivation of Mullerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc Natl Acad Sci U S A 1996; 93: 7711-7716
    CrossrefPubMedGoogle Scholar